In clinical trials the treatment — which involves extracting individual patients» immune T - cells, modifying them to seek out tell -
tale biological markers associated with blood cancers like aggressive lymphoma, and then pumping those modified killer cells back into the body — has shown major promise, in some cases eliminating all signs of the cancer in patients six months after treatment.